SB 440 is a broad government-operations and health-policy bill that revises multiple titles of Georgia law, with its main focus on the Department of Public Health and related health oversight programs. It updates the prescription drug monitoring program (PDMP) by refining prescriber enrollment and review requirements, removing certain board powers and advisory committee provisions, and clarifying that prescribers who fail to comply are subject to administrative, but not civil, liability. The bill also creates a pharmacist dispensing exception for ivermectin when it is FDA-approved, properly labeled, and dispensed after a good-faith patient assessment, with rules to be set by the State Board of Pharmacy.
Beyond controlled substances, the bill repeals or revises several older public-health and health-education provisions, including AIDS/HIV marriage-license materials, sickle cell information, newborn hearing-screening reporting, auto-injectable epinephrine reporting, neonatal abstinence syndrome reporting, the Cancer Advisory Committee, the cancer control officer position, the Osteoporosis Prevention and Treatment Education Act, the Georgia Commission for Saving the Cure, and the Arthritis Prevention and Control Program. It also transfers certain home-delivered meals duties to the Department of Public Health, revises reporting for stroke and cardiac care programs, and updates the newborn cord blood/postnatal tissue bank framework.
In addition, SB 440 makes insurance and behavioral-health changes. It requires health insurers to approve complete credentialing applications within 45 days, directs the Department of Insurance and the Department of Community Health to develop a standardized credentialing application, and requires insurers to use that application by July 1, 2027. In mental health, it expands the Behavioral Health Coordinating Council, creates a parity compliance review panel, and requires health care providers to report suspected mental health parity violations so the panel can evaluate complaints and recommend punitive action to the appropriate regulators.
The bill’s impact on state law is substantial because it amends or repeals provisions across public health, insurance, mental health, taxation, and social services. It shifts administrative duties within state agencies, removes several reporting and advisory requirements, creates new oversight mechanisms for mental health parity, and imposes new operational deadlines on insurers and the Department of Insurance. It also delays implementation until July 1, 2026, with some insurance-related deadlines extending into 2027.
The overall sentiment appears generally favorable but not unanimous. The Senate passed the bill 49-0 after earlier amendment votes that were narrower, while the House passed it 97-75, indicating broader support in the House but also meaningful opposition. The lack of committee transcript material limits insight into debate, but the vote pattern suggests the bill was viewed as a significant modernization package with some contested provisions.
The main points of contention likely involved the bill’s mix of repeals and new mandates. Potentially controversial items include the ivermectin exception, the elimination of long-standing reporting and advisory structures, the removal of some public-health program requirements, and the new mental health parity reporting obligations placed on providers and insurers. Supporters likely emphasized modernization, administrative streamlining, and stronger parity enforcement, while opponents may have objected to the breadth of the bill, the repeal of existing programs, or the new compliance burdens on health care stakeholders.
SB 440 amends Titles 16, 19, 31, 33, 37, 48, and 49 of the Official Code of Georgia Annotated, affecting controlled substances oversight, public health administration, insurance credentialing, mental health parity enforcement, tax checkoff contributions, and social services funding. It removes or revises several statutory reporting and advisory requirements, creates a pharmacist-dispensing pathway for ivermectin, requires standardized insurer credentialing procedures, and establishes a parity compliance review panel with complaint-review and recommendation authority. The bill also repeals several legacy public-health programs and updates duties related to newborn screening, cancer services, cord blood banking, and elderly and child nutrition services.
The bill appears to have received mixed but ultimately favorable legislative treatment. It passed the Senate unanimously on final passage after amendment votes and then passed the House by a narrower margin, suggesting support for the overall modernization package but some disagreement over specific provisions. The absence of transcript excerpts limits direct evidence of floor debate, but the voting history indicates the measure was considered significant and somewhat divisive rather than routine.
Likely areas of contention include the ivermectin exception, the repeal of older public-health programs and committees, the reduction or elimination of reporting requirements, and the new obligations placed on health care providers and insurers regarding mental health parity complaints. Supporters likely framed these changes as modernization, administrative efficiency, and improved enforcement, while critics may have viewed them as overbroad, as weakening certain public-health functions, or as imposing new compliance burdens on providers and insurers. The House vote margin suggests these issues drew more resistance there than in the Senate.